“……… The CD17 trial was designed in collaboration with our partners at Einstein ARO and BIOMM to have an adequately powered interim analysis after 40% of the patients have been enrolled and completed 28 days of treatment with leronlimab. Given that average weekly cases currently are over 35,000, we anticipate that the results of the interim analysis may be available in the next three to four months using the endpoints we refined from CD12…….”

I would of expected interim results sooner than 3-4 months.